LifePoint Health, Inc. (LPNT) Rating Lowered to Sell at Zacks Investment Research
LifePoint Health, Inc. (NASDAQ:LPNT) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday.
According to Zacks, “LifePoint Health’s stock has underperformed the industry in last three months. The company is faced with increasing expenses which has outpaced revenue growth thereby squeezing operating margins. The company is suffering from low patient admissions. High bad debt is another concern. Following second-quarter results, the company trimmed its 2017 guidance on a challenging volume environment and weak revenue growth. The stock has seen the Zacks Consensus Estimate for current-year earnings being revised 2.9% downward over the last 60 days.”
Several other analysts also recently issued reports on LPNT. ValuEngine downgraded shares of LifePoint Health from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. TheStreet lowered LifePoint Health from a “b-” rating to a “c+” rating in a research report on Wednesday, August 16th. BidaskClub cut LifePoint Health from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Royal Bank Of Canada reaffirmed a “buy” rating and set a $77.00 target price on shares of LifePoint Health in a research note on Wednesday, July 5th. Finally, Leerink Swann upgraded LifePoint Health from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $73.00 to $74.00 in a report on Tuesday, June 6th. Four investment analysts have rated the stock with a sell rating, nine have issued a hold rating and two have given a buy rating to the company. LifePoint Health currently has a consensus rating of “Hold” and a consensus price target of $66.00.
Shares of LifePoint Health (NASDAQ LPNT) remained flat at $58.65 during trading on Tuesday. 188,867 shares of the stock traded hands. LifePoint Health has a 12 month low of $50.60 and a 12 month high of $70.95. The company has a 50 day moving average price of $56.97 and a 200-day moving average price of $61.41. The company has a market cap of $2.35 billion, a PE ratio of 13.13 and a beta of 0.84.
LifePoint Health (NASDAQ:LPNT) last released its quarterly earnings results on Tuesday, August 1st. The company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.90 by $0.06. LifePoint Health had a net margin of 2.61% and a return on equity of 7.40%. The firm had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.64 billion. During the same period in the previous year, the company earned $0.69 EPS. The firm’s revenue for the quarter was up .2% compared to the same quarter last year. On average, equities analysts forecast that LifePoint Health will post $4.06 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This report was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/10/03/lifepoint-health-inc-lpnt-rating-lowered-to-sell-at-zacks-investment-research-2.html.
In other news, Chairman William F. Carpenter III sold 17,653 shares of the stock in a transaction on Monday, July 17th. The stock was sold at an average price of $65.06, for a total transaction of $1,148,504.18. Following the transaction, the chairman now owns 439,841 shares of the company’s stock, valued at approximately $28,616,055.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 8.76% of the stock is currently owned by corporate insiders.
Several institutional investors have recently made changes to their positions in the company. Dynamic Technology Lab Private Ltd bought a new stake in shares of LifePoint Health in the second quarter valued at about $872,000. WINTON GROUP Ltd lifted its stake in LifePoint Health by 138.4% in the second quarter. WINTON GROUP Ltd now owns 93,705 shares of the company’s stock worth $6,292,000 after acquiring an additional 54,400 shares during the period. Dean Capital Management lifted its stake in LifePoint Health by 68.0% in the second quarter. Dean Capital Management now owns 67,143 shares of the company’s stock worth $4,508,000 after acquiring an additional 27,180 shares during the period. Ameritas Investment Partners Inc. lifted its stake in LifePoint Health by 2.6% in the second quarter. Ameritas Investment Partners Inc. now owns 12,080 shares of the company’s stock worth $811,000 after acquiring an additional 305 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its stake in LifePoint Health by 2.8% in the second quarter. The Manufacturers Life Insurance Company now owns 59,357 shares of the company’s stock worth $3,986,000 after acquiring an additional 1,629 shares during the period. Hedge funds and other institutional investors own 99.53% of the company’s stock.
LifePoint Health Company Profile
LifePoint Health, Inc, through its subsidiaries, owns and operates community hospitals, regional health systems, physician practices, outpatient centers and post-acute facilities. As of December 31, 2016, the Company operated 72 hospital campuses in 22 states, having a total of 9,424 licensed beds. It offers a range of general and specialized healthcare services to patients through a network of hospitals and outpatient facilities.
Receive News & Stock Ratings for LifePoint Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifePoint Health Inc. and related stocks with our FREE daily email newsletter.